
Jamal A Mikdashi MD
Associate Professor, Medicine, University of Maryland School of Medicine
Join to View Full Profile
820 Linden AveSte 209Baltimore, MD 21201
Phone+1 410-706-6474
Fax+1 410-706-0231
Dr. Mikdashi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
MedStar Health Georgetown University/Georgetown HospitalResidency, Internal Medicine, 1989 - 1991
Johns Hopkins UniversityFellowship, Rheumatology, 1987 - 1988
American University of Beirut Faculty of MedicineClass of 1984
Certifications & Licensure
MD State Medical License 1989 - 2027
VA State Medical License 1990 - 2016
American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2016
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2015-2016
- Super Doctor SuperDoctors.com
Clinical Trials
Publications & Presentations
PubMed
- 1 citationsDiscontinuation versus continuation of maintenance treatment with tumor necrosis factor inhibitors in patients with rheumatoid arthritis with low disease activity or r...Michael M Ward, Arthur Weinstein, Paloma Alejandro-Silva, Alan K Matsumoto, Rukmini Konatalapalli
Seminars in Arthritis and Rheumatism. 2025-12-01 - 1 citationsSystemic Sarcoidosis With Neurosarcoidosis Features as a Risk Factor for Multifocal Osteonecrosis.Hee Jae Jung, Jamal Mikdashi
Cureus. 2024-08-01 - 2 citationsLong-term outcome of status epilepticus-related to systemic lupus erythematosus: An observational study and a systematic review.Jamal Mikdashi, Allan Krumholz
Seminars in Arthritis and Rheumatism. 2023-12-01
Press Mentions
Baltimore Company Designing Rheumatoid Arthritis Drug Gets OK from FDA to Start Testing on PatientsOctober 12th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









